I.1-2 Efficacy of Pemetrexed maintenance in Patients of Metastatic Non-squamous Non-small-cell Lung Cancer. Single Center Experience. Academic Hospital IMSS XXI Century

Abstract

Pemetrexed has been approved for maintenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC). The purpose of this study was to describe real-world maintenance use of pemetrexed in Mexico City Oncology Hospital IMSS. It was a retrospective study and where included files of patients with advanced nonsquamous NSCLC metastatic received carboplatin (area under the curve, 5), gemcitabine (1250 mg/m2) o pemetrexed (500 mg/m2) and carboplatin (area under the curve 5) for four cycles to six cycles. Patients without progression after four cycles to six cycles received pemetrexed (500 mg/m2) until progression. The primary point was response, SLP. 16 patients have radiotherapy in oligometastatic disease concomitant with radiotherapy. We evaluated 35 files of patients with demographic/clinical factors: median age 60 years (45-78 years), gender (35% female and 62% male), about smoking status there were 65% positive, brain metastases (8.5%), median of cycles were 11.4 (51cycles -2 cycles) and follow-up of 24 months and median progression free survival of 8.2 months (95% CI: 8.8-7.5). Pemetrexed is efficacious as maintenance therapy for advanced nonsquamous NSCLC and we had better progression free survival. However, it should be evaluated in a prospective study.